TY - JOUR
T1 - Polyvinylamine with moderate binding affinity as a highly effective vehicle for RNA delivery
AU - Tian, Ye
AU - Zhao, Yipu
AU - Yin, Chong
AU - Tan, Shenxing
AU - Wang, Xue
AU - Yang, Chaofei
AU - Zhang, Tuo Di
AU - Zhang, Xi
AU - Ye, Fei
AU - Xu, Jing
AU - Wu, Xianglong
AU - Ding, Li
AU - Zhang, Jie
AU - Pei, Jiawei
AU - Wang, Xue Ting
AU - Zhang, Rui Xue
AU - Xu, Jianrong
AU - Wang, Weisi
AU - Filipe, Carlos D.M.
AU - Hoare, Todd
AU - Yin, Da Chuan
AU - Qian, Airong
AU - Deng, Xudong
N1 - Publisher Copyright:
© 2022
PY - 2022/5
Y1 - 2022/5
N2 - Polymeric carriers for RNA therapy offer potential advantages in terms of low immunogenicity, promoting modifiability and accelerating intracellular transport. However, balancing high transfection efficacy with low toxicity remains challenging with polymer-based vehicles; indeed, polyethyleneimine (PEI) remains the “gold standard” polymer for this purpose despite its significant toxicity limitations. Herein, we demonstrate the potential of polyvinylamine (PVAm), a commodity high-charge cationic polymer used in the papermaking industry and has similar structure with PEI, as an alternative carrier for RNA delivery. High levels of transfection of normal, tumor, and stem cells with a variety of RNA cargoes including small interfering RNA (siRNA), microRNA (miRNA), and recombinant RNA can be achieved in vitro under the proper complex conditions. While, both the anti-tumor effect achieved in a xenograft osteosarcoma model and lipid-lowering activity observed in a hyperlipidemia mice indicate the potential for highly effective in vivo activity. Of note, both the transfection efficiency and the cytotoxicity of PVAm compare more favorably with those of PEI, with PVAm offering the additional advantages of simpler purification and significantly lower cost. In addition, the mechanism for the difference in transfection efficiency between PVAm and PEI is explored by molecular docking as well as analyzing the process of association and dissociation between polymers (PVAm and PEI) and nucleic acids. Our research provides a novel, non-toxic, and cost-effective carrier candidate for next generation RNA therapy, and elucidates the potential mechanism of PVAm for its efficient delivery of RNA.
AB - Polymeric carriers for RNA therapy offer potential advantages in terms of low immunogenicity, promoting modifiability and accelerating intracellular transport. However, balancing high transfection efficacy with low toxicity remains challenging with polymer-based vehicles; indeed, polyethyleneimine (PEI) remains the “gold standard” polymer for this purpose despite its significant toxicity limitations. Herein, we demonstrate the potential of polyvinylamine (PVAm), a commodity high-charge cationic polymer used in the papermaking industry and has similar structure with PEI, as an alternative carrier for RNA delivery. High levels of transfection of normal, tumor, and stem cells with a variety of RNA cargoes including small interfering RNA (siRNA), microRNA (miRNA), and recombinant RNA can be achieved in vitro under the proper complex conditions. While, both the anti-tumor effect achieved in a xenograft osteosarcoma model and lipid-lowering activity observed in a hyperlipidemia mice indicate the potential for highly effective in vivo activity. Of note, both the transfection efficiency and the cytotoxicity of PVAm compare more favorably with those of PEI, with PVAm offering the additional advantages of simpler purification and significantly lower cost. In addition, the mechanism for the difference in transfection efficiency between PVAm and PEI is explored by molecular docking as well as analyzing the process of association and dissociation between polymers (PVAm and PEI) and nucleic acids. Our research provides a novel, non-toxic, and cost-effective carrier candidate for next generation RNA therapy, and elucidates the potential mechanism of PVAm for its efficient delivery of RNA.
KW - Binding affinity
KW - Gene therapy
KW - Polymeric nanocomplex
KW - Polyvinylamine
KW - RNA delivery
KW - RNA-polymer interaction
UR - http://www.scopus.com/inward/record.url?scp=85126750259&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2022.03.003
DO - 10.1016/j.jconrel.2022.03.003
M3 - 文章
C2 - 35248648
AN - SCOPUS:85126750259
SN - 0168-3659
VL - 345
SP - 20
EP - 37
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -